Coagulation Factors

FDA Approves Gene Therapy for Hemophilia B

Click here for CSL Behring’s press release from November 22, 2022, announcing FDA approval of etranacogene dezaparvovec [Hemgenix] for adult Hemophilia B [factor IX deficient] patients.

Bleeding Disorders

Poster: a Handheld Fibrinogen Assay Device

The qLab FIB is a recently introduced handheld point-of-care device that returns a fibrinogen result within ten minutes using a single drop of citrated whole blood.

ISTH Poster: FVIII Deficient Plasma with VWF

Yesterday, July 12, 2022, at the ISTH annual meeting in London, England, the research staff of Precision BioLogic Inc., Dartmouth, Nova Scotia, Canada presented the poster: Kesavan N, Rahman M, Sadeghi-Khomami A, Black KM, Wood A. Performance of FVIII deficient plasma with VWF in the activity measurement of FVIII replacement products in plasma samples using […]

Bleeding Disorders

ISTH Poster: Chromogenic FIX Activity Assay

Yesterday, July 12, 2022, at the ISTH annual meeting in London, England, the research staff of Precision BioLogic Inc., Dartmouth, Nova Scotia, Canada presented the poster: Quinton T, Fraser J, Black KM, Sadeghi-Khomami A. Performance of a chromogenic factor IX activity assay in the recovery of factor IX replacement therapies, Abstract PB1183. Their data illustrate […]

Bleeding Disorders

November 2021 QQ: Case Study, Prolonged PTT, Response

Our November 2021 Quick Question Case attracted 75 responses. We asked, “A 3-YOA female with normal PT and prolonged PTT and no bleeding. What is the most likely deficiency?” Here are your responses: Factor V–3 [4%] Factor VIII–18 [20%] Factor IX–2 [3%] Factor XI–4 [7%] Factor XII–44 [59%] Factor XIII–4 [7%] Congenital factor V deficiency […]

Coagulation Factors

August, 2021 Quick Question: Factor Deficiency

Our August 2021 Quick Question, which asks, “Which factor deficiency causes the smallest risk of bleeding?” drew a respectable 48 votes. Answers: VWF deficiency: 9% [4] Factor X deficiency: 4% [2] Factor XI deficiency: 7% [3] Factor XII deficiency: 52% [24] Prekallikrein deficiency: 28% [13] Both 4 and 5 are correct, deficiencies of contact factors […]

Bleeding Disorders

Chromogenic Factor IX Assay

The Precision BioLogic Inc. and the Affinity Biologicals, Inc. research team presented a poster describing the recovery characteristics of a new chromogenic factor IX assay at the July 17–21, 2021 meeting of the International Society on Thrombosis and Haemostasis. The poster is now available for your download: Tara Quinton, Rachel Clarke, John Fraser, Karen M. […]

Bleeding Disorders

Chromogenic Factor IX Assay

Click here to see the Precision BioLogic research team’s latest poster, Quinton T, Clarke R, Fraser J, Black KM, Sadeghi-Khomami A. Validation of a New Kit for the Quantitative Determination of Chromogenic Factor IX Activity. This poster was presented at the July 17–21 ISTH meeting.

Bleeding Disorders

New Fundamentals in Hemostasis

Thanks to my colleague Carlo Ledesma, MS, SH(ASCP)QLS, MT(ASCPi), MT(AMT) for pointing me to an in-depth hemostasis review, Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New Fundamentals in Hemostasis. Physiol Rev 2013;93:327–58. This is a valuable teaching resource that helps elucidate the cell-based hemostasis model.

Arterial Thrombosis

Extended Half-life FVIII & FIX and the PTT

From Carolyn McCarville: Hi George, My small laboratory is trying to figure out the best management of coag samples from patients receiving extended half life factor replacement products. We understand that many of the one stage clotting factor assays are inaccurate for the wealth of these products. One thing that we cannot get a straight […]

Bleeding Disorders

Load more

George Fritsma is a medical laboratory scientist, educator, and author. George is a member of the International Society on Thrombosis and Hemostasis, the International Society for Laboratory Hematology, and the American Society for Clinical Laboratory Science.

Cheat Sheets from George

Quick Question